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ABSTRACT 
Background: Amongst the 3 approved oral P2Y12 inhibitors for the treatment of patients with 
acute coronary syndrome (ACS), ticagrelor, but not prasugrel or clopidogrel, has been 
associated to off-target properties, such as improved endothelial-dependent vasomotion and 
increased adenosine plasma levels. 
Methods: The Hunting for the off-target propertIes of Ticagrelor on Endothelial function and 
other Circulating biomarkers in Humans (HI-TECH) study (N T02587260) is a 
multinational, randomized, open-label, cross-over study with a Latin squares design, 
conducted at 5 European sites, in which patients free from recurrent ischemic or bleeding 
events ≥30 days after a qualifying ACS were allocated to sequentially receive a 30±5-day 
treatment with prasugrel, clopidogrel, and ticagrelor in random order. The primary objective 
was to evaluate whether ticagrelor, at treatment steady state (i.e. after 30±5 days of drug 
administration), as compared with both clopidogrel and prasugrel, is associated with an 
improved endothelial function, assessed with peripheral arterial tonometry., Thirty-six 
patients undergoing evaluable endothelial function assessment for each of the assigned P2Y12 
inhibitor were needed to provide 90% power to detect a 10% relative change of the reactive 
hyperemia index (RHI) in the ticagrelor group. 
Conclusion: The HI-TECH study is the first randomized, cross over study aiming to ascertain 
whether ticagrelor, when administered at approved regimen in post-ACS patients, improves 
endothelial function as compared with both clopidogrel and prasugrel. 
 
Word count abstract: 218 words 
Key words: endothelial function, acute coronary syndromes, off-target properties, ticagrelor, 
reactive hyperemia index, adenosine, pulse amplitude tonometry, flow mediated dilation. 
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Highlights 
 The off-target properties of ticagrelor on endothelial function are poorly studied 
 HI-TECH compares ticagrelor, prasugrel and clopidogrel in post-ACS patients 
 The principal endpoint of the study is the effect on endothelial function evaluated with 
pulse amplitude tonometry 
 Measurement of adenosine plasma levels is a key secondary endpoint 
 Platelet reactivity will be also assessed 
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Background  
Oral P2Y12 inhibitors are key secondary prevention medications after coronary stent 
implantation or acute coronary syndromes (ACS). Ticagrelor, unlike other oral P2Y12 
inhibitors, has been associated with off-target effects, such as an improvement in endothelial 
function assessed by peripheral arterial tonometry, as recently reported in a non-randomized 
trial (1). Moreover, in a recent randomized trial of 60 ACS patients, 30-day ticagrelor 
administration was shown to increase reactive hyperemia index (RHI) by 100% as compared 
to baseline measurement, and this improvement to be correlated to adenosine plasma levels 
(2). A recent observational study also reported no change in endothelial function at 2 and 5 
days after treatment discontinuation with ticagrelor, which was interpreted as evidence that 
the treatment effect on endothelial function does not immediately cease after treatment 
cessation (3).  
Endothelial dysfunction is a systemic condition mainly characterized by an imbalance 
between endothelium-derived relaxing factors (i.e. nitric oxide) (4) and endothelium-derived 
contracting factors (i.e. endothelin) (5), clinically correlated with most cardiovascular risk 
factors(6). Endothelial dysfunction appears to precede the clinical manifestation of 
atherosclerotic disorders and predicts clinical outcome (7). Thus, it can be considered a 
barometer of the total risk burden (8-10).  
The “ticagrelor-related pleiotropic effects” are possibly mediated by the inhibition of 
adenosine uptake into erythrocytes and subsequent increase in adenosine plasma levels 
(APL), as recently reported (2,11,12). 
Adenosine is released in the plasma by endothelial cells and myocytes during ischemia, 
hypoxia, or oxidative stress, and quickly taken up by red blood cells through a facilitated 
diffusion transport system (sodium-independent equilibrative nucleoside transporters – 1 
(ENT-1) and 2 (ENT-2); sodium-dependent concentrative nucleoside transporters – 1 and 2) 
or converted into inosine by adenosine deaminase activity. Ticagrelor increases APL mainly 
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through inhibition of ENT-1 (11). After binding to 4 different purinergic receptors (A1, A2A, 
A2B, A3), an increase in APL may determine: 1) vasodilation; 2) reduction in 
ischemia/reperfusion injury and electrical conduction; 3) increase of platelet inhibition; 4) 
decrease of glomerular filtration rate; 5) rise of dyspnoea incidence. Finally, ticagrelor 
induces adenosine tri-phosphate (ATP) release from human red blood cells in a dose-
dependent manner (13), which may contribute to increasing APL. It remains however unclear 
whether the off-target properties of ticagrelor, which were discovered and characterized in 
animals or ex vivo models (14,15), contribute to its clinical effects in humans at currently 
approved regimen. 
 
Methods 
Study design and population 
The HI-TECH study (ClinicalTrial.gov NCT02587260) is a multinational, randomized, open-
label, crossover study with a Latin squares design conducted at 5 European sites and including 
54 patients, aiming to assess whether ticagrelor, as compared to both clopidogrel and 
prasugrel, improves endothelial function. Eligible patients were older than 18 years, treated 
for an ACS, including ST segment elevation myocardial infarction (STEMI), non-ST segment 
elevation myocardial infarction (NSTEMI), or unstable angina (UA), at least 30 days before 
randomization, and receiving dual antiplatelet therapy (DAPT) since at least 30 days prior to 
randomization. Patients were free from bleeding events [defined as Bleeding Academic 
Research Consortium (BARC) classification (16) type 2 or greater] or ischemic recurrences 
(unstable angina or myocardial infarction, which required a repeated revascularization) since 
the index event. Patients with transient ischemic attack (TIA) or stroke in the previous 6 
months, those who received fibrinolytic therapy or glycoprotein IIb/IIIa inhibitors in the 
previous 30 days, those with indication for oral anticoagulant therapy, or with vasculitis, 
immunological disorders, thrombocytopenia, severe hepatic failure, uncontrolled hypertension 
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(systolic or diastolic pressure > 180 mmHg or 120 mmHg, respectively, despite medical 
therapy), known intolerance to aspirin, clopidogrel, prasugrel, or ticagrelor, limited life 
expectancy (e.g. neoplasm) as well as patients who underwent major surgery within 30 days 
before randomization or with any planned surgical or percutaneous intervention were 
excluded (Tab. 1). 
A Latin square design was used in order to have a uniform crossover design in that each 
treatment occurred only once within each sequence and once within each period. Moreover, 
each treatment preceded every other treatment the same number of times (twice) and, 
consequently, our design was balanced with respect to first-order carryover effects (balanced 
Latin square design). The crossover study design was chosen so to have an “in within” control 
of the effect of each P2Y12 inhibitor on endothelial function (in the same patient) as opposed 
to an “in between” control (different patients). Supplementary Table 1 displays the 6 
randomized treatment sequences. Adherence to study treatment was assessed by electronic 
Medication Event Monitoring System (MEMS), pill count, and patient interview (see Suppl. 
Appendix). 
 
Follow-up visits 
The study included 6 follow-up visits counting a total of 10 study intervals: baseline (B), 1-2 
hour(s) after LD intake of each P2Y12 inhibitor (C1, P1, T1), before (C2, P2, T2) and 1-2 
hour(s) after MD intake of each P2Y12 inhibitor (C3, P3, T3) (Fig. 1). The LD of the first 
randomized P2Y12 inhibitor was to be administered at visit 1 (V1), after baseline assessment, 
followed by post-LD measurements 1-2 hour(s) thereafter (Fig. 1). Pre- and post-MD 
evaluations of the ongoing P2Y12 inhibitor were to be performed after 30±5 days of treatment 
at visit 2 (V2). The administration of the second randomized P2Y12 inhibitor at visit 3 (V3) 
was to occur 1 to 7 days after V2, and the related measurements were collected 1-2 hour(s) 
after LD administration (Fig. 1). An identical scheme was then to be followed for the second 
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and third randomized P2Y12 inhibitor (Fig. 1). No washout time was allowed among the three 
oral P2Y12 inhibitors due to ethics considerations. At each follow-up, patients were requested 
to fast for at least 2 hours prior the visit; caffeine-containing beverages were not permitted at 
any time the day of the visit. Patients were reminded 1-2 days prior each study visit about 
these dietary restrictions. 
 
Finger Plethysmography 
Pulse amplitude tonometry (PAT) is an operator-independent, FDA-approved method to 
measure the endothelium-dependent dilation in response to reactive hyperemia (10). The PAT 
device records digital pulse wave amplitude using fingertip plethysmography (EndoPAT; 
Itamar Medical Ltd, Caesarea, Israel) and quantifies the endothelium-mediated changes in 
vascular tone, elicited by a 5-minute occlusion of the brachial artery. A post-occlusion to pre-
occlusion ratio (Fig. 2) is calculated by the EndoPAT
TM
 software and expressed as RHI; Fig. 
2a) or its natural logarithm variant (LnRHI; Fig. 2b). These values are normalized to 
measurements from the contra-lateral arm, which serves as control for non-endothelial 
dependent systemic effects. An RHI value less than 1.67 or an LnRHI value less than 0.51 
denotes an endothelial dysfunction (8). EndoPAT was found to be well correlated with 
coronary endothelial function, evaluated by quantitative coronary angiography after injection 
of acetylcholine (8), as well as with the conventional cardiovascular risk factors (17,18). 
EndoPAT measurement was able to identify patients with early coronary atherosclerosis (8) 
and predicts late cardiovascular adverse events (10). EndoPAT reliability was tested in 
healthy adults and adolescents and it was shown to be highly reproducible across intervals of 
1 day (19) and 1 week or longer (20-22). Description of technical procedure is reported in the 
Suppl. Appendix. 
Methodological advantages of this technology are: 1) simultaneous recording from both arms 
with an intra-subject control; 2) live assessment of occlusion and provocation quality in order 
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to avoid incomplete occlusion during the exam; 3) large dynamic range of measurements due 
to the finger ability to vary local vascular tone; 4) operator independency as all analyses are 
automated. Limitations is this assessment include: 1) the assessment of endothelial function at 
a microcirculation level instead of at medium to large size vessel such as the brachial artery, 
as assessed via standard flow mediated dilatation 2) the use of a fixed time frame during the 
hyperaemic response to calculate the EndoScore, while the maximal hyperaemic response can 
occur with different delays for each patient, especially in older subjects (23); 3) the influence 
of autonomous nervous system or the temperature study room on finger vascular tone; 4) 
limited knowledge about the effect of circadian variation on RHI result. 
 
Flow Mediated Dilation. 
Flow Mediated Dilation (FMD) of brachial artery is a non-invasive technique widely used to 
assess endothelial function. The FMD result is reported as a percentage change between the 
peak diameter in response to reactive hyperaemia, after 5 minutes of artery occlusion, and the 
baseline diameter using the following equation: 
FMD (%) = (Peak diameter – Baseline diameter)/Baseline diameter * 100 
Moreover, the FMD evaluation after nitrate administration is able to differentiate the 
endothelium-independent vasodilation component due to alterations in smooth and not 
endothelial cell function, improving the endothelial function assessment. However, although 
the principle seems simple and many laboratories showed robust test-retest reliability for 
FMD under standardized conditions (24-26), appropriate high-resolution ultrasound 
equipment and highly skilled personnel are essential for obtaining an accurate and reliable 
measurement (18,20,27). Ghiadoni et al. evaluated the FMD twice in the same day and 
subsequently after 30 days after a dedicated training program in the setting of a multicenter 
evaluation of 135 healthy volunteers (27). FMD values did not differ over time and showed an 
intra-session coefficient of variation ranging from 7.6% to 11.9% and an inter-session 
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coefficient of variation ranging from 11.6% to 16.1% across centres. No data has been 
however provided in CAD patients who may have higher intra and inter-session variability. 
Furthermore, it remains challenging to standardise FMD protocol and technical expertise 
across different sites. Therefore, we evaluated the endothelial function using the FMD jointly 
to the EndoPAT technology (Fig. 3), only in one study center– Bern University Hospital, 
Switzerland, with large prior experience with this methodology (28-31). Description of 
technical procedure is reported in the Suppl. Appendix. 
 
Circulating biomarkers 
Plasma levels of various circulating biomarkers have been associated with the presence of 
endothelial dysfunction. Endothelin-1 (ET-1) is a 21-amino-acid peptide synthesized from a 
larger preproET-1 precursor that elicits its vasoconstrictor properties binding two G-protein 
coupled receptors, ETA and ETB, located on vascular smooth muscle cells, fibroblasts, and 
endothelial cells (ETB only). ET-1 induces endothelial dysfunction reducing NO 
bioavailability through 2 different ways: 1) Decreasing its production via caveolin-1-mediated 
inhibition of eNOS activity; 2) Increasing its degradation via formation of oxygen radicals 
(32). Accordingly, high levels of ET-1 may represent an indirect index of endothelial 
dysfunction. 
Asymmetric dimethylarginine (ADMA) is an analogue of L-arginine found in human 
circulation and represents a naturally occurring endogenous inhibitor of NO synthase (33). 
Reducing NO production, ADMA could thus lead to endothelial dysfunction and 
cardiovascular events. Elevated plasma ADMA concentration has been identified as an 
independent risk factor for progression of atherosclerosis, cardiovascular death, and all-cause 
mortality (34-36).  
Von Willebrand factor (vWF) is a multimeric glycoprotein synthesised exclusively in 
endothelial cells and megakaryocytes and released when endothelial cells are damaged. Thus, 
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high level of circulating vWF may reflect endothelium damage or endothelial dysfunction. 
The close association between vWF and thrombogenensis or atherogenesis also suggests that 
high vWF levels may be a useful indirect indicator of atherosclerosis and/or thrombosis (37). 
 Blood collection was to be performed after EndoPAT assessment at each time point, using 
the control arm as sampling site for the quantification of ADMA, vWF antigen, and ET-1. To 
assess the relationship between residual platelet reactivity or percentage inhibition and effect 
of P2Y12 oral blocker on endothelial function, a platelet function testing was also to be carried 
out using the VerifyNow system using both P2Y12 and aspirin assays.  
Markers of thrombin activity such as prothrombin fragment 1+2, fibrinopeptide A, and 
thrombin-antithrombin complex (TAT) were also measured for exploratory purpose. All 
circulating biomarkers reported above were predefined and will be analysed by a centralized 
laboratory (Istituti Clinici Scientifici Maugeri - IRCCS Lumezzane, Brescia, Italy). C-reactive 
protein will be measured with an immunoturbidimetric assay, while all the other biomarkers 
will be measured using commercially available ELISA tests (Suppl. Tab. 2), including the 
vWF antigen, for which the ELISA test is a well validated method of measurement (38-40). 
Finally, to provide mechanistic data on how ticagrelor may be associated with improved 
endothelial function, adenosine plasma concentration (APC), ticagrelor and its metabolite 
AR-C124910XX will be dosed in two different reference laboratories (Q&Q labs AB, Bio 
VentureHub, Mölndal, Sweden, and Bioanalytical Covance Laboratory, Indianapolis, United 
States, respectively). An overview of all investigated biomarkers with the corresponding 
collection time points are shown in Suppl. Tab. 3. Protocols of sample collection, 
centrifugation, and storage were standardized in all sites (pre-analytical standardization) and 
are reported in Suppl. Tab. 4. When immediately frozen at -20°C (as stored in Amsterdam, 
Barcelona, Pavia, and Bern), or -80°C (as stored in Rotterdam), after centrifugation and never 
thawed, all assessed biomarkers are known to be stable in vitro for a long time (at least few 
years). The only exception is represented by adenosine, which is immediately degraded after 
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blood collection with a half-life of a few seconds. In order to improve adenosine stability and 
allow its subsequent dosage, a stopping solution was immediately added to blood tube during 
sampling. 
 
Collection of Adenosine samples. 
Adenosine plasma samples were collected as described by Bonello et al (12). Venous blood 
(2.6 ml) was withdrawn under vacuum together with a STOP solution previously placed in S-
Monovette® 2.6 ml, K3 EDTA (Sarstedt, Nümbrecht, Germany). This method allows blood 
sample to be mixed rapidly with 4 mL of STOP solution, which prevents adenosine 
degradation and uptake. The STOP solution was composed of NBMPR 0.1 mml/L, 
dipyridamole 0.04 mmol/L, AMPCP 0.22 mmol/L, ethylene-diamine-tetraacetic acid 
disodium salt dehydrate 15 mmol/L, 5-iodotubericidin 0.1 mmol/L, and erythro-9-(2-hydroxy-
3-nonyl)-adenine (EHNA) 0.1 mmol/L dissolved in PBS, pH 7.4, 0.01 mmol/L (Suppl. Tab. 
5). The sample with the STOP solution was centrifuged at 1640xg for 10 minutes at room 
temperature. The plasma supernatant was then transferred in a dedicated micro-tube and then 
stored at -20°C or, preferably, -80°C. 
 
Randomization 
Allocation of study treatment was performed via a Web-based interactive randomization 
system available at https://trials.advicepharma.com/hitech. Randomization was achieved with 
computer-generated random sequence with a random block size (from X to Y) stratified 
according to the clinical site and the presence of diabetes mellitus. 
 
Treatment protocol and Follow-up 
All patients received DAPT for the entire duration of the study, which included aspirin (75-
160 mg/day orally) and, in random order, clopidogrel (600 mg orally as LD followed by 75 
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mg/day) for 30±5 days, prasugrel (60 mg orally as LD followed by 10 mg/day, or 5 mg/day if 
age ≥ 75 years and/or weight ≤ 60 Kg) for 30±5 days, and ticagrelor (180 mg orally as LD 
followed by 90 mg twice a day) for 30±5 days. Follow-up visit schedule is shown in figure 1.  
 
Study endpoints 
The primary objective of the study is RHI at treatment steady state (i.e. after 30±5 days of 
treatment), evaluated with EndoPAT system and assessed 1-2 hour(s) after intake of the daily 
(for clopidogrel or prasugrel) or morning (for ticagrelor) maintenance dose of each 
investigated P2Y12 inhibitor. The primary endpoint consists of two main comparisons: 
ticagrelor vs. prasugrel difference in RHI, and ticagrelor vs. clopidogrel difference in RHI.  
The secondary objectives include RHI 1-2 hour(s) after P2Y12 inhibitor loading dose or prior 
MD administration and other biomarkers of endothelial function. Each of these secondary 
endpoints encompasses two main comparisons: ticagrelor vs. prasugrel difference, and 
ticagrelor vs. clopidogrel difference. The comparison between prasugrel and clopidogrel in 
terms of RHI and circulating biomarkers will be also reported for exploratory purposes. 
 
Statistical considerations 
The null hypothesis (H0) of this study is that the primary endpoint (difference in RHI at 
treatment steady state) does not differ during ticagrelor treatment as compared with prasugrel 
or clopidogrel. The alternative hypothesis (H1) is that the primary endpoint differs after 
ticagrelor as compared to prasugrel or clopidogrel. Sample size calculation was based on 
repeated two-way ANOVA (20), setting mean RHI at 1.8 with a within subjects standard 
deviation (SD) of 0.31. Hence, 36 patients completing all sequences (i.e. 6 patients/sequence) 
provides 90% power to detect a 10% RHI relative change in ticagrelor group with a two-sided 
alpha level at 5%. To account for dropouts as well as incomplete data assessments, the final 
sample size was increased up to ≥50 patients. 
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The primary endpoint will be analysed using repeated measures one-factorial analysis of 
variance (ANOVA with 3 levels as treatment factor to account for each of the three tested 
P2Y12 inhibitor). Correction for possible intra-group correlation will be done by the 
Greenhouse-Geisser method. The ANOVA will yield the differences between the two main 
comparisons ticagrelor RHI vs. prasugrel RHI and ticagrelor RHI vs. clopidogrel RHI. To 
assess the primary endpoint, the significance of these two main comparisons will be combined 
using the Hochberg-Benjamini method (41) as follows: the H0 of randomized treatment 
equivalence comparing the response in RHI after ticagrelor vs. prasugrel administration, and 
the response in RHI after ticagrelor vs. clopidogrel administration, is rejected if significance is 
achieved for both main comparisons at a two-sided alpha level of 0.05 (i.e. the difference in 
RHI ticagrelor vs. prasugrel is supported with p-value < 0.05 and the difference in RHI 
ticagrelor vs. clopidogrel is supported with p-value < 0.05); or for one comparison at a two-
sided alpha level of 0.025 (i.e. the difference in RHI ticagrelor vs. prasugrel is supported with 
p-value < 0.025 or the difference in RHI ticagrelor vs. clopidogrel is supported with p-value < 
0.025). 
Each of the secondary endpoints will be analysed using the same pre-defined statistical 
assumptions, combining the p-values of the two main comparisons. The H0 will be rejected if 
either comparison yields a p-value < 0.025 or when both comparisons yield p-values < 0.05. 
See Suppl. appendix for further explanation and for examples regarding the application of the 
Benjamini-Hochberg in our experimental setting (Suppl. Table 6). 
The third comparison (i.e. the difference in response between prasugrel and clopidogrel) will 
be reported as explorative unpowered endpoint. 
The SWAP-2 study showed that switching over to prasugrel from previous treatment with 
ticagrelor results in a progressive decline in PLT inhibition (leading to a clear rebound effect 
if no LD is given) as compared to the continuation of treatment with ticagrelor. Hence, it may 
be assumed that any measurement performed during the early phase of any switch from one to 
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another P2Y12 inhibitor may be confounded (i.e. it may also at least partially reflect prior 
exposure to the earlier P2Y12 inhibitor). Based on the timing of blood sampling in this study, 
one may assume this carry-over effect to disappear from after 48 hours and up to 7 days. This 
was the rational for setting the primary EP measure remotely, i.e. at 30 days after each cross 
over. Nevertheless, methodologies that account for any possible carry-over effect, such as 
ANCOVA and stratified analysis based on the randomized sequence as well as non-
randomized type of P2Y12 inhibitor before randomization, will be applied for multiple 
sensitivity analyses for all primary and secondary endpoints. It is also pre-specified that for 
these sensitivity analyses, clopidogrel and prasugrel will be handled separately as well as 
lumped together in the thienopyridines group. 
Stratified analysis of the primary endpoint will be also carried out according to: sex, age, 
presence of diabetes, hypertension, active smoking, dyslipidaemia, BMI, study site, number of 
vessels diseased, type of ACS at presentation, randomization sequence, and pre-
randomization P2Y12 inhibitor intake. 
 
Predefined sub-analyses and sub-studies 
Pre-specified sub-analyses and sub-studies include, but are not limited to, the evaluation of 
adenosine plasma concentration, adherence to study drugs, effect of age or concomitant drugs 
on primary or secondary endpoint measures of endothelial function and FMD results. 
 
Study organization 
The HI-TECH study was conducted at 5 investigative sites in 4 European countries, including 
Switzerland, Italy, Spain, and The Netherlands. The final study protocol and informed consent 
have been reviewed and approved by the ethics boards/institutional review boards and 
corresponding health authorities for all participant study sites/countries. The study is an 
investigator-driven clinical trial partially supported by an unrestricted research grant from 
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AstraZeneca. The authors are solely responsible for the design and conduct of this study; all 
study analyses, and drafting and editing of the manuscript. Data are being coordinated and 
analysed by an academic Clinical Trial Unit (CTU) located in Bern, Switzerland. The trial 
registration number is NCT02587260 available at 
https://register.clinicaltrials.gov/prs/app/action/LoginUser?uid=U0002SC5&ts=167&cx=-
f91kzu. Independent study monitoring was performed by AdvicePharma (Milan, Italy). The 
Electronic Data Capture (EDC) was designed by the investigators and web-implemented by 
AdvicePharma.  
 
Conclusions 
The HI-TECH study is the first randomized, cross over study aiming to ascertain whether 
ticagrelor, when administered at approved regimen in post-ACS patients, improves 
endothelial function as compared with both clopidogrel and prasugrel. The first patient was 
randomized on December 2015 and the last on October 2016 with a total of 54 patients. The 
last follow-up visit was performed on February 2017 and the final results are expected in Q3 
2017.  
 
Acknowledgements 
Conflicts of interest: 
Salvatore Brugaletta received lectures fees from AstraZeneca, Abbott, and Boston, and has 
received institutional research grant from AstraZeneca. Sergio Leonardi received personal 
fees from AstraZeneca, The Medicine Company, Merck, Daiichi Sankyo, Ely Lilly and 
institutional research grants from AstraZeneca and Daiichi Sankyo. K. Stephan Windecker 
received research contracts to the institution from Abbott, Biotronik, Boston Scientifc, 
Medtronic, Edwards Lifesciences and St Jude. Marco Valgimigli has received speakers fees 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 17 
from AstraZeneca, Biosensor, and Terumo, and has received institutional research grants from 
AstraZeneca, The Medicines Company, and Terumo. Other authors have nothing to declare.  
 
Contributorship: 
MV designed the study and obtained funding; MV and SA contributed to protocol 
development; MV and SA actively participated in the writing of the manuscript; DH 
contributed to the statistical analysis and actively participated in the writing of the statistical 
sections of the manuscript; all authors critically reviewed the manuscript and approved the 
final version. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 18 
References 
1. Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor improves peripheral 
arterial function in patients with a previous acute coronary syndrome. Cardiology 
2013;124:252-8. 
2. Fromonot J, Dignat-Georges F, Rossi P et al. Ticagrelor Improves Peripheral Arterial 
Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma 
Level. J Am Coll Cardiol 2016;67:1967-8. 
3. Xanthopoulou I, Vogiatzi C, Bampouri T et al. Lack of Evidence for Deterioration in 
Endothelial Function Following Ticagrelor Treatment Cessation. Curr Vasc Pharmacol 
2016;14:487-491. 
4. Flammer AJ, Luscher TF. Human endothelial dysfunction: EDRFs. Pflugers Arch 
2010;459:1005-13. 
5. Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction: EDCFs. Pflugers 
Arch 2010;459:1015-23. 
6. Flammer AJ, Anderson T, Celermajer DS et al. The assessment of endothelial 
function: from research into clinical practice. Circulation 2012;126:753-67. 
7. Halcox JP, Schenke WH, Zalos G et al. Prognostic value of coronary vascular 
endothelial dysfunction. Circulation 2002;106:653-8. 
8. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Jr., Kuvin JT, Lerman A. 
Noninvasive identification of patients with early coronary atherosclerosis by 
assessment of digital reactive hyperemia. J Am Coll Cardiol 2004;44:2137-41. 
9. Kuvin JT, Patel AR, Sliney KA et al. Assessment of peripheral vascular endothelial 
function with finger arterial pulse wave amplitude. Am Heart J 2003;146:168-74. 
10. Rubinshtein R, Kuvin JT, Soffler M et al. Assessment of endothelial function by non-
invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur 
Heart J 2010;31:1142-8. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 19 
11. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence 
and potential clinical relevance. J Am Coll Cardiol 2014;63:2503-9. 
12. Bonello L, Laine M, Kipson N et al. Ticagrelor increases adenosine plasma 
concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 
2014;63:872-7. 
13. Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D. Ticagrelor induces adenosine 
triphosphate release from human red blood cells. Biochem Biophys Res Commun 
2012;418:754-8. 
14. Grzesk G, Kozinski M, Navarese EP et al. Ticagrelor, but not clopidogrel and 
prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-
controlled study in rats. Thromb Res 2012;130:65-9. 
15. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. 
Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically 
relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol 
Ther 2014;19:209-19. 
16. Mehran R, Rao SV, Bhatt DL et al. Standardized bleeding definitions for 
cardiovascular clinical trials: a consensus report from the Bleeding Academic 
Research Consortium. Circulation 2011;123:2736-47. 
17. Hamburg NM, Keyes MJ, Larson MG et al. Cross-sectional relations of digital 
vascular function to cardiovascular risk factors in the Framingham Heart Study. 
Circulation 2008;117:2467-74. 
18. Sauder KA, West SG, McCrea CE et al. Test-retest reliability of peripheral arterial 
tonometry in the metabolic syndrome. Diab Vasc Dis Res 2014;11:201-7. 
19. Liu J, Wang J, Jin Y, Roethig HJ, Unverdorben M. Variability of peripheral arterial 
tonometry in the measurement of endothelial function in healthy men. Clin Cardiol 
2009;32:700-4. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 20 
20. McCrea CE, Skulas-Ray AC, Chow M, West SG. Test-retest reliability of pulse 
amplitude tonometry measures of vascular endothelial function: implications for 
clinical trial design. Vasc Med 2012;17:29-36. 
21. Selamet Tierney ES, Newburger JW, Gauvreau K et al. Endothelial pulse amplitude 
testing: feasibility and reproducibility in adolescents. J Pediatr 2009;154:901-5. 
22. Tomfohr LM, Martin TM, Miller GE. Symptoms of depression and impaired 
endothelial function in healthy adolescent women. J Behav Med 2008;31:137-43. 
23. Black MA, Cable NT, Thijssen DH, Green DJ. Importance of measuring the time 
course of flow-mediated dilatation in humans. Hypertension 2008;51:203-10. 
24. Harris RA, Padilla J, Hanlon KP, Rink LD, Wallace JP. Reproducibility of the flow-
mediated dilation response to acute exercise in overweight men. Ultrasound Med Biol 
2007;33:1579-85. 
25. Jarvisalo MJ, Jartti L, Marniemi J et al. Determinants of short-term variation in arterial 
flow-mediated dilatation in healthy young men. Clin Sci (Lond) 2006;110:475-82. 
26. Donald AE, Halcox JP, Charakida M et al. Methodological approaches to optimize 
reproducibility and power in clinical studies of flow-mediated dilation. J Am Coll 
Cardiol 2008;51:1959-64. 
27. Ghiadoni L, Faita F, Salvetti M et al. Assessment of flow-mediated dilation 
reproducibility: a nationwide multicenter study. J Hypertens 2012;30:1399-405. 
28. Bailey DM, Rimoldi SF, Rexhaj E et al. Oxidative-nitrosative stress and systemic 
vascular function in highlanders with and without exaggerated hypoxemia. Chest 
2013;143:444-51. 
29. Jayet PY, Rimoldi SF, Stuber T et al. Pulmonary and systemic vascular dysfunction in 
young offspring of mothers with preeclampsia. Circulation 2010;122:488-94. 
30. Rimoldi SF, Rexhaj E, Pratali L et al. Systemic vascular dysfunction in patients with 
chronic mountain sickness. Chest 2012;141:139-46. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 21 
31. Rimoldi SF, Sartori C, Rexhaj E et al. Antioxidants improve vascular function in 
children conceived by assisted reproductive technologies: A randomized double-blind 
placebo-controlled trial. Eur J Prev Cardiol 2015;22:1399-407. 
32. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J 
Cardiovasc Pharmacol 2007;50:621-8. 
33. Sibal L, Agarwal SC, Home PD, Boger RH. The Role of Asymmetric 
Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. 
Curr Cardiol Rev 2010;6:82-90. 
34. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical 
dimethylarginine and adverse cardiovascular events after percutaneous coronary 
intervention. Eur Heart J 2003;24:1912-9. 
35. Valkonen VP, Paiva H, Salonen JT et al. Risk of acute coronary events and serum 
concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8. 
36. Meinitzer A, Seelhorst U, Wellnitz B et al. Asymmetrical dimethylarginine 
independently predicts total and cardiovascular mortality in individuals with 
angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular 
Health study). Clin Chem 2007;53:273-83. 
37. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in 
vascular disorders? Cardiovasc Res 1997;34:255-65. 
38. Zhukov O, Popov J, Ramos R et al. Measurement of von Willebrand factor-FVIII 
binding activity in patients with suspected von Willebrand disease type 2N: 
application of an ELISA-based assay in a reference laboratory. Haemophilia 
2009;15:788-96. 
39. Castaman G, Tosetto A, Cappelletti A et al. Validation of a rapid test (VWF-LIA) for 
the quantitative determination of von Willebrand factor antigen in type 1 von 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 22 
Willebrand disease diagnosis within the European multicenter study MCMDM-
1VWD. Thromb Res 2010;126:227-31. 
40. Vinholt PJ, Overgaard M, Diederichsen AC et al. An ELISA for the quantitation of 
von Willebrand factor: osteoprotegerin complexes in plasma. Thromb Res 
2013;131:396-400. 
41. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance 
testing. Stat Med 1990;9:811-8. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 23 
Figure legend 
Figure 1. Study design 
Study flow-chart depicting study visits with the respective time intervals (black arrows on 
top) and all procedures performed at each time-point. Endothelial function evaluation is 
performed using EndoPAT in all sites while FMD was performed only for patients recruited 
in Bern. Blood was collected for dosage of circulating biomarkers. VerifyNow measurements, 
using both P2Y12 and ASA assays were obtained to assess platelet reactivity. ACS=Acute 
Coronary Syndrome; V1=visit one; V2=visit two; V3=visit three; V4=visit four; V5=visit 
five; V6=visit six; LD=loading dose; MD=maintenance dose; T1=1-2 hours after ticagrelor 
LD administration; T2=before ticagrelor MD administration; T3=1-2 hours after ticagrelor 
MD administration; P1=1-2 hours after prasugrel LD administration; P2=before prasugrel MD 
administration; P3=1-2 hours after prasugrel MD administration; C1=1-2 hours after 
clopidogrel LD administration; C2=before clopidogrel MD administration; C3=1-2 hours 
after clopidogrel MD administration; S=sequence; P=prasugrel; T=ticagrelor; C=clopidogrel; 
h=hour(s). 
 
Figure 2. EndoPAT
TM
 Measurement 
Figure 2a. Reactive hyperemia index (RHI) measurement after EndoPAT
TM
 assessment. 
A=mean PAT amplitude between 90s-150s post-occlusion of the test arm; B=mean PAT 
amplitude from the baseline period on the test arm; C=mean PAT amplitude between 90s-
150s post-occlusion of the control arm; D=mean PAT amplitude from the baseline period of 
the control arm. 
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Figure 2b. Natural logarithm of Reactive Hyperemia Index (LnRHI) measurement after 
EndoPAT
TM
 assessment. A=mean PAT amplitude between 90s-120s post-occlusion of the test 
arm; B=mean PAT amplitude from the baseline period on the test arm; C=mean PAT 
amplitude between 90s-120s post-occlusion of the control arm; D=mean PAT amplitude from 
the baseline period of the control arm. 
 
Figure 3. FMD and EndoPAT assessment at Bern University Hospital. 
The picture shows the concomitant acquisition of FMD and EndoPAT measurements at Bern 
University Hospital. 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 25 
Table 1. Inclusion and exclusion criteria 
Inclusion Criteria 
1. Age > 18 years 
2. ACS (including STEMI or NSTEMI) at least 30 days before randomization 
3. Ongoing treatment with DAPT since at least 30 days, consisting of ASA 75-160 mg 
daily and one of the three available P2Y12 inhibitors (ticagrelor, prasugrel or 
clopidogrel)  
4. No bleeding events (defined as BARC type 2 or greater) or ischemic recurrences in 
the period between the ACS and the study randomization 
Exclusion Criteria 
1. Administration of fibrinolytics or glycoprotein IIb/IIIa inhibitors in the previous 30 
days 
2. Major surgery within 30 days or any planned surgical or percutaneous intervention 
3. Active bleeding or previous clinically relevant bleeding in the last 6 months 
4. Previous TIA or stroke in the last 6 months 
5. Previous intracranial bleeding 
6. Thrombocytopenia 
7. Ongoing anticoagulant therapy or clinical indication to start with anticoagulant agents 
8. Vasculitis or any known immunological disorder 
9. Severe hepatic failure 
10. Uncontrolled hypertension (systolic or diastolic arterial pressure > 180 mmHg or 120 
mmHg, respectively, despite medical therapy) 
11. Known intolerance to aspirin, clopidogrel, prasugrel, or ticagrelor 
12. Limited life expectancy (i.e. neoplasms) 
13. Inability to obtain the informed consent 
14. Pregnancy 
ACS=acute coronary syndrome; STEMI=ST segment elevation myocardial infarction; 
NSTEMI=non-ST segment elevation myocardial infarction; DAPT=dual antiplatelet therapy; 
ASA=aspirin; BARC=bleeding academic research consortium; TIA=transient ischemic attack 
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